0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Complement C5

Complement C5

Complement C5 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CO5-R52H4 Rabbit Rabbit Complement C5 Protein, His Tag
CO5-R52H4-structure
CO5-R52H4-sds
CO5-H52H7 Human Human Complement C5 (w917s) Protein, His Tag
CO5-H52H7-structure
CO5-H52H7-sds
CO5-H52H7-elisa_1
CO5-H52Hx Human Human Complement C5 (R885H) Protein, His Tag
CO5-H52Hx-structure
CO5-H52Hx-sds
CO5-H52Hx-elisa_1
CO5-C52Hx Cynomolgus Cynomolgus Complement C5 Protein, His Tag
CO5-C52Hx-structure
CO5-C52Hx-sds
CO5-C52Hx-elisa_1
CO5-R52H5 Rat Rat Complement C5 Protein, His Tag
CO5-R52H5-structure
CO5-R52H5-sds
CO5-R52H5-elisa_1
CO5-M52H4 Mouse Mouse Complement C5 Protein, His Tag
CO5-M52H4-structure
CO5-M52H4-sds
CO5-M52H4-elisa_1
CO5-H52Ha Human Human Complement C5 Protein, His Tag
CO5-H52Ha-structure
CO5-H52Ha-sds
CO5-H52Ha-elisa_1

Complement C5 Part of Bioactivity data

CO5-H52Hx-ELISA
Human Complement C5 (R885H), His TagHuman Complement C5 (R885H), His Tag (Cat. No. CO5-H52Hx) ELISA bioactivity

Immobilized Human Complement C5 (R885H), His Tag (Cat. No. CO5-H52Hx) at 2 μg/mL (100 μL/well) can bind Anti-C5a (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).

CO5-H52H7-ELISA
Human Complement C5 (w917s), His TagHuman Complement C5 (w917s), His Tag (Cat. No. CO5-H52H7) ELISA bioactivity

Immobilized Human Complement C5 (w917s), His Tag (Cat. No. CO5-H52H7) at 2 μg/mL (100 μL/well) can bind Anti-C5a MAb (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).

Complement C5 Molecule Synonym Name

Complement C5,C5,CPAMD4

Complement C5 Molecule Background

Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Complement C5 References

Complement C5 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Eculizumab LEX-98; HAL-1; h-5G1.1; 5G1-1,LEX98,HAL1 Approved Alexion Pharmaceuticals SOLIRIS fda Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (AHUS) ALEXION PHARM 2007-03-16 Myasthenia gravis, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (AHUS), Neuromyelitis optica (NMO) Details
Ravulizumab ALXN-1210; ALXN-1810,ALXN 1210; ALXN 1810; ALXN1210; ALXN1810 Approved Alexion Pharmaceuticals ULTOMIRIS fda Paroxysmal Nocturnal Hemoglobinuria (PNH) ALEXION PHARM 2018-12-21 Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (AHUS) Details

Complement C5 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Pexelizumab Phase Ⅲ Stanford University, Alexion Pharmaceuticals Reperfusion injury, Myocardial infarction (MI) Details
ALXN-1720 ALXN-1720,ALXN1720 Phase Ⅰ Alexion Pharmaceuticals Unspecified Details
Tesidolumab LFG-316; NOV-4 Phase Ⅱ MorphoSys, Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Details
IFX-1 CaCP-29; IFX-1 Phase Ⅲ Beijing Mabworks Biotech, InflaRx Coronavirus Disease 2019 (COVID-19) Details
JPD-003 JPD-003 Phase Ⅰ JARI Pharmaceutical Inflammation Details
BDB-001 BDB-001,BDB001; BDB 001 Phase Ⅲ Staidson (Beijing) Biopharmaceuticals Age-related macular degeneration (AMD) Details
Cemdisiran ALN-CC5 Phase Ⅱ Alnylam Haemolytic uraemic syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH) Details
Eculizumab biosimilar (Amgen) ABP-959 Phase Ⅲ Amgen Haemolytic uraemic syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH) Details
Eculizumab biosimilar (Samsung Bioepis) SB-12 Phase Ⅲ Samsung Bioepis, C-Bridge Capital Partners Paroxysmal Nocturnal Hemoglobinuria (PNH) Details
Crovalimab CH-7092230; RG-6107; RO-7092230; RO-7112689; RO-7112689/F01; SKY-59 Phase Ⅲ Chugai, Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Details
SOBI-002 SOBI-002 Phase Ⅰ Swedish Orphan Biovitrum Autoimmune diseases, Inflammation Details
Pozelimab REGN-3918 Phase Ⅲ Regeneron Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Details
ALXN-5500 ALXN-5500 Phase Ⅰ Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Details
Avacincaptad pegol ARC-187; ARC-1905 Phase Ⅲ Archemix Dry age related macular degeneration (AMD) Details
Eculizumab biosimilar (CinnaGen) Phase Ⅲ CinnaGen Paroxysmal Nocturnal Hemoglobinuria (PNH) Details
Eculizumab biosimilar (IBC GENERIUM) Phase Ⅲ IBC Generium Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (AHUS) Details
Eculizumab biosimilar (Biocad) BCD-148 Phase Ⅲ Biocad Paroxysmal Nocturnal Hemoglobinuria (PNH) Details
Nomacopan EV-576; rEV-576; rVA576 Phase Ⅲ Evolutec, Akari Haemolytic uraemic syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH) Details
Zilucoplan RA-101495; RA-101495-SC Phase Ⅲ Ra Pharma Myasthenia gravis, Haemolytic uraemic syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH), Lupus nephritis Details
Olendalizumab ALXN-1007 Phase Ⅱ Alexion Pharmaceuticals Transplant rejection, Inflammation, Antiphospholipid syndrome Details
TAC-401 TAC-401 Phase Ⅱ Taiho Pharma Helicobacter infections Details

This web search service is supported by Google Inc.

totop